XNAS · Healthcare · Biotechnology
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -1.43 | -2.15 | -50.35% | $0 | ❌ Miss | -0.41% | -4.81% | — |
| 2026-03-19 | Q4 2025 | -2.45 | -2.11 | +13.88% | $0 | ✅ Beat | -0.26% | +1.42% | +36.01% |
| 2025-11-14 |
| Q3 2025 |
| -2.21 |
| -2.28 |
| -3.17% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | -2.73 | -1.85 | +32.23% | $1.3M | ✅ Beat | -0.47% | +3.56% | +16.76% |
| 2025-03-17 | Q4 2024 | — | -3.09 | — | $100,000 | — | +0.43% | +5.60% | -17.72% |
| 2024-11-14 | Q3 2024 | -3.38 | -2.84 | +15.98% | $0 | ✅ Beat | -3.49% | -2.44% | +1.60% |
| 2024-08-13 | Q2 2024 | -1.47 | 125.48 | +8636.05% | $100,000 | ✅ Beat | -0.09% | +14.25% | +33.45% |
| 2024-02-28 | Q4 2023 | -1.04 | -1.73 | -66.35% | $1.6M | ❌ Miss | -1.00% | -3.49% | -5.76% |
Showing last 8 quarters.